<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T01:38:01Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/29318" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/29318</identifier><datestamp>2026-09-24T05:26:56Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Matino, Davide</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Dadashi Zadeh, Ghazaleh</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Sciences (Blood and Cardiovascular)</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2024-01-04T16:27:29Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2024-01-04T16:27:29Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2024</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/29318</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/21944</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Abstract&#xd;
 Background: Hemophilia A is an X-linked bleeding disorder characterized by a deficiency or absence of FVIII. Patients can develop anti-FVIII IgG, rendering FVIII therapy ineffective. Antibody production can be suppressed by targeting CD32b receptors in B cells using ICs. Binding rhFVIII/anti-FVIII immune complexes (rhFVIII-ICs) to FcγRIIB (CD32b) leads to phosphorylation of the immune receptor tyrosine-based inhibition motif (ITIM) tail of CD32b, resulting in the transduction of inhibitory signals to B cells, thereby inhibiting antibody production.  &#xd;
Aim: To evaluate the effect of rhFVIII-ICs administration on the suppression of antibody production by B cells in a mouse model. &#xd;
Methods: A high-affinity anti-FVIII IgG pool was obtained by immunizing of FVIII KO mice with rhFVIII (Kovaltry). After immunization, blood was collected from immunized mice, and plasma was obtained. rhFVIII-ICs were prepared by incubating the mice plasma or anti-FVIII monoclonal antibody pool with Kovaltry at 1:1 and 1:10 ratios. FVIII KO mice were injected retro-orbitally with rhFVIII-ICs, PBS, or Kovaltry diluted in naïve plasma once weekly for four weeks (tolerization phase). Next, the mice were administered with FVIII retro-orbitally at a dose of 25 IU/kg once weekly for four weeks. Finally, blood samples were collected from all mice, and ELISA determined the concentration of anti-FVIII IgG. &#xd;
Results: Mice that received the combination of FVIII and naive plasma developed anti-FVIII IgG (mean increase 6.1 μg/mL, p-value = 0.0001). In contrast, 69% of mice that received 1:1 rhFVIII-ICs did not develop antibodies (mean increase 1.3 μg/mL, p-value = 0.0723), while 50% of the mice that received 1:10 rhFVIII-ICs did not develop antibodies (mean increase 2.3 μg/mL, p-value = 0.1030). &#xd;
Conclusion: In this study, we demonstrated that a 1:1 balanced ratio of rhFVIII-ICs injection suppresses antibody production. Thus, antibody feedback may play a role in the immune response to FVIII by suppressing FVIII-specific B cells. Future work will investigate the mechanism of this suppression, particularly the potential involvement of CD32b.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Hemophilia A</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Mouse Model</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Inhibitor</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Anti-FVIII antibody</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">The role of FVIII/Anti-FVIII antibody Immune Complexes in Preventing FVIII-Specific Antibody Production in a Hemophilia A Mouse Model</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>